NYSE:MED Medifast (MED) Stock Price, News & Analysis → Alert: Your Bank is Dying – Act Now or Lose Everything! (From Priority Gold) (Ad) Free MED Stock Alerts $20.15 -0.57 (-2.75%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$19.87▼$20.8350-Day Range$20.15▼$35.5352-Week Range$19.87▼$109.52Volume456,542 shsAverage Volume521,003 shsMarket Capitalization$220.44 millionP/E Ratio3.25Dividend YieldN/APrice Target$49.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Medifast alerts: Email Address Medifast MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside146.9% Upside$49.75 Price TargetShort InterestBearish32.30% of Float Sold ShortDividend StrengthN/ASustainability-4.07Upright™ Environmental ScoreNews Sentiment0.31Based on 11 Articles This WeekInsider TradingN/AProj. Earnings Growth94.68%From $0.94 to $1.83 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.61 out of 5 starsConsumer Staples Sector65th out of 134 stocksMiscellaneous Food Preparations & Kindred Products Industry2nd out of 4 stocks 2.8 Analyst's Opinion Consensus RatingMedifast has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days.Read more about Medifast's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted32.30% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Medifast has recently increased by 6.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth. Previous Next 1.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedifast has received a -4.19% net impact score from Upright. The largest negative impact of Medifast in category "GHG emissions" seems to be driven mostly by its "Meal replacement soups", "Meal replacement bars", "Meal replacement drinks", and "Protein bars" products. See details.Environmental SustainabilityThe Environmental Impact score for Medifast is -4.07. Previous Next 2.4 News and Social Media Coverage News SentimentMedifast has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Medifast this week, compared to 4 articles on an average week.Search InterestOnly 13 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.MarketBeat Follows7 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medifast are expected to grow by 94.68% in the coming year, from $0.94 to $1.83 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 3.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 3.25, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 20.36.Price to Book Value per Share RatioMedifast has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTop-Secret Government Project RevealedDetails a top-secret program for taking America’s most critical technology mainstream. And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.To get all the details of this new tech – click here now. About Medifast Stock (NYSE:MED)Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Read More MED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MED Stock News HeadlinesMay 28, 2024 | marketbeat.comLifeMD Can Surge on Its GLP-1 Offerings (MED)LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a resultJune 14 at 6:37 AM | investorplace.com3 Stocks to Sell as Ozempic Surges in PopularityJune 12 at 1:20 PM | investorplace.com7 Small-Cap Value Stocks Leaving the S&P 500 in the DustJune 11 at 1:18 AM | americanbankingnews.comResearch Analysts Set Expectations for Medifast, Inc.'s Q2 2024 Earnings (NYSE:MED)June 7, 2024 | prnewswire.comKKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600June 7, 2024 | americanbankingnews.comMedifast, Inc. Expected to Earn FY2024 Earnings of $0.70 Per Share (NYSE:MED)June 6, 2024 | americanbankingnews.comMedifast (NYSE:MED) Downgraded by DA DavidsonMay 24, 2024 | seekingalpha.comMedifast: Significant Undervaluation Even As Struggles PersistMay 22, 2024 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the FirmMay 22, 2024 | finance.yahoo.comInvestors Could Be Concerned With Medifast's (NYSE:MED) Returns On CapitalMay 20, 2024 | investorplace.comInvest in the Underestimated: 7 Bargain Stocks Poised to Prove Wall Street WrongMay 20, 2024 | finance.yahoo.comMedifast Continues Business Transformation, Launching National Marketing Campaign Promoting its Holistic Offering for Customers Utilizing and Considering Weight Loss MedicationsMay 20, 2024 | businesswire.comMedifast Continues Business Transformation, Launching National Marketing Campaign Promoting its Holistic Offering for Customers Utilizing and Considering Weight Loss MedicationsMay 18, 2024 | sg.finance.yahoo.comMED Jun 2024 65.000 putMay 16, 2024 | bizjournals.comMedifast closes Maryland warehouse, lays off 62 workersMay 13, 2024 | investorplace.comPocket-Sized Powerhouses: 7 Small-Cap Value Stocks Ready to RoarMay 9, 2024 | finance.yahoo.comQ1 2024 LifeMD Inc Earnings CallMay 6, 2024 | finance.yahoo.comEarnings To Watch: Nature's Sunshine (NATR) Reports Q1 Results TomorrowMay 1, 2024 | msn.comMedifast Just Hit Its 20th 5-Year Low. Are You Smart/Dumb Enough to Buy?May 1, 2024 | finance.yahoo.comMedifast, Inc. (NYSE:MED) Q1 2024 Earnings Call TranscriptMay 1, 2024 | ca.investing.comOlaplex Earnings: What To Look For From OLPXMay 1, 2024 | finance.yahoo.comMedifast First Quarter 2024 Earnings: EPS Misses ExpectationsApril 30, 2024 | za.investing.comMedifast stock plunges on earnings miss, weak outlookApril 30, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Consumer Cyclical Stocks: The Chefs’ Warehouse (CHEF), Medifast (MED) and Marine Products (MPX)April 30, 2024 | finance.yahoo.comWhy Medifast (MED) Shares Are Trading Lower TodaySee More Headlines Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/29/2024Today6/14/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees634Year FoundedN/APrice Target and Rating Average Stock Price Target$49.75 High Stock Price Target$82.00 Low Stock Price Target$17.50 Potential Upside/Downside+146.9%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$6.20 Trailing P/E Ratio3.25 Forward P/E Ratio21.44 P/E GrowthN/ANet Income$99.42 million Net Margins7.55% Pretax Margin9.70% Return on Equity36.64% Return on Assets23.16% Debt Debt-to-Equity RatioN/A Current Ratio2.84 Quick Ratio2.25 Sales & Book Value Annual Sales$1.07 billion Price / Sales0.21 Cash Flow$10.55 per share Price / Cash Flow1.91 Book Value$18.50 per share Price / Book1.09Miscellaneous Outstanding Shares10,940,000Free Float10,664,000Market Cap$220.44 million OptionableOptionable Beta1.16 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Daniel R. Chard (Age 59)Executive Chairman & CEO Comp: $1.94MMr. James P. Maloney CPA (Age 56)Chief Financial Officer Comp: $823.91kMr. Anthony E. Tyree (Age 59)Chief Business Operations Officer Comp: $655.86kMr. Jason L. Groves Esq. (Age 53)Executive VP, General Counsel & Corporate Secretary Comp: $669.51kMr. Nicholas M. Johnson (Age 44)Chief Field Operations Officer Comp: $696.4kMr. Jonathan Barrett MacKenzie (Age 52)VP of Finance & Chief Accounting Officer Mr. Steven ZenkerVice President of Investor RelationsMs. Claudia C. Greninger (Age 51)Chief Human Resources Officer More ExecutivesKey CompetitorsUSANA Health SciencesNYSE:USNANu Skin EnterprisesNYSE:NUSNature's Sunshine ProductsNASDAQ:NATRVeruNASDAQ:VERUEstée Lauder CompaniesNYSE:ELView All CompetitorsInsiders & InstitutionsBurney Co.Bought 20,064 shares on 5/22/2024Ownership: 0.183%Swedbank ABBought 3,000 shares on 5/21/2024Ownership: 0.027%Virtu Financial LLCBought 5,975 shares on 5/20/2024Ownership: 0.055%Walleye Trading LLCSold 1,000 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 591 shares on 5/16/2024Ownership: 0.099%View All Insider TransactionsView All Institutional Transactions MED Stock Analysis - Frequently Asked Questions Should I buy or sell Medifast stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" MED shares. View MED analyst ratings or view top-rated stocks. What is Medifast's stock price target for 2024? 2 Wall Street research analysts have issued 12-month target prices for Medifast's shares. Their MED share price targets range from $17.50 to $82.00. On average, they expect the company's share price to reach $49.75 in the next twelve months. This suggests a possible upside of 146.9% from the stock's current price. View analysts price targets for MED or view top-rated stocks among Wall Street analysts. How have MED shares performed in 2024? Medifast's stock was trading at $67.22 at the beginning of the year. Since then, MED stock has decreased by 70.0% and is now trading at $20.15. View the best growth stocks for 2024 here. When is Medifast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our MED earnings forecast. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) posted its earnings results on Monday, April, 29th. The specialty retailer reported $0.66 EPS for the quarter, missing the consensus estimate of $0.78 by $0.12. The specialty retailer earned $174.74 million during the quarter, compared to analyst estimates of $168.90 million. Medifast had a net margin of 7.55% and a trailing twelve-month return on equity of 36.64%. The firm's revenue for the quarter was down 49.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.67 EPS. How often does Medifast pay dividends? What is the dividend yield for Medifast? Medifast declared a quarterly dividend on Thursday, September 7th. Shareholders of record on Tuesday, September 19th will be paid a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 32.75%. The ex-dividend date is Monday, September 18th. Read our dividend analysis for MED. What ETFs hold Medifast's stock? ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD), Invesco S&P SmallCap Consumer Staples ETF (PSCC) and Global X Health & Wellness ETF (BFIT). What guidance has Medifast issued on next quarter's earnings? Medifast issued an update on its second quarter 2024 earnings guidance on Monday, April, 29th. The company provided earnings per share guidance of 0.050-0.400 for the period, compared to the consensus earnings per share estimate of 0.780. The company issued revenue guidance of $150.0 million-$170.0 million, compared to the consensus revenue estimate of $168.9 million. What is Daniel Chard's approval rating as Medifast's CEO? 44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM). Who are Medifast's major shareholders? Medifast's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.27%), Jacobs Levy Equity Management Inc. (1.59%), PEAK6 Investments LLC (0.00%), Principal Financial Group Inc. (0.59%), Allspring Global Investments Holdings LLC (0.39%) and Inspire Advisors LLC (0.30%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:MED) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.